WO1998031788A1 - Formulations injectables destinees au traitement d'os osteoporotiques - Google Patents

Formulations injectables destinees au traitement d'os osteoporotiques Download PDF

Info

Publication number
WO1998031788A1
WO1998031788A1 PCT/US1998/001143 US9801143W WO9831788A1 WO 1998031788 A1 WO1998031788 A1 WO 1998031788A1 US 9801143 W US9801143 W US 9801143W WO 9831788 A1 WO9831788 A1 WO 9831788A1
Authority
WO
WIPO (PCT)
Prior art keywords
bone
bmp
rhbmp
active agent
proteins
Prior art date
Application number
PCT/US1998/001143
Other languages
English (en)
Inventor
Alexandre Valentin-Opran
Stephen B. Trippel
John M. Wozney
Howard Seeherman
Thomas Turek
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Priority to AU62458/98A priority Critical patent/AU6245898A/en
Publication of WO1998031788A1 publication Critical patent/WO1998031788A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24

Definitions

  • the present invention relates to the field of tissue repair, specifically, to the treatment of osteoporotic bone and/or prevention of osteoporosis.
  • Osteoporotic or osteopenic bone is often characterized by suboptimal bone density.
  • the osteoporotic condition may be related to diet, trauma or stress, or to degenerative or congenital disease.
  • the present invention may be useful in the treatment and/or the prevention of osteoporosis, or the treatment of osteoporotic or osteopenic bone.
  • Idiopathic osteoporosis is a disease of unknown etiology characterized by progressive loss of bone mass and increased fragility. It is a medical problem because it is associated with a marked increase in susceptibility to fractures. It is a public health problem for several reasons.
  • hip fractures are currently the most common fracture in the elderly.
  • Praemer et ai Ibid.
  • Estimates based on census projections indicate that this figure will increase to approximately 340,000 hip fractures per year by the year 2000.
  • One out of every six Caucasian women will have a hip fracture during her lifetime (Cummings et al, Arch Intern Med 49:2455-2458 (1989), and for those who attain the age of 90, this figure becomes one in three.
  • approximately 20 percent remain in a long term care institution for at least one year following the fracture.
  • proximal femur fracture During the first year following injury, the mortality rate is approximately 15% higher than for age and gender matched controls. Praemer et al., Ibid. The financial toll of these fractures is also high. In 1988, hip fractures cost the United States 8.7 billion dollars. Praemer et al., Ibid. The increased incidence of proximal femur fracture observed in elderly patients is mainly related to two factors: (1) a decreased bone density of their proximal femora; (2) an increased propensity to fall. There is an inverse relationship between the age-related bone loss in the proximal femur and the risk of hip fracture.
  • Bioactive agents that reduce the incidence of hip fractures or augment the healing of such fractures when they occur would substantially improve the health of the elderly.
  • the availability of an injectable agent would permit its use in fracture prevention, such as hip fracture, without the costs and morbidity of surgical intervention, such as for femoral neck fractures.
  • Such an agent would have application in fracture treatment, without increasing the extent or complexity of the surgical management.
  • the inventors have provided a novel method using bioactive agents to decrease the occurrence and/or severity of fractures to osteoporotic bone, such as an osteoporotic hip.
  • the present invention provides methods and compositions for increasing bone mass and quality, and for minimizing or reducing the incidence or severity of osteoporosis-related fractures. Accordingly, the present invention provides methods and compositions useful for decreasing the incidence of fractures of osteoporotic or osteopenic bone.
  • the present invention comprises methods of treating patients with osteoporosis, or with other evidence of osteoporosis or osteopenic condition.
  • Preferred embodiments where the present invention may prove particularly useful include treatment of metaphyseal bone, including proximal femur (hip), proximal humerus (upper arm), distal radius (wrist), and vertebral bodies (spine), particularly the vertebral body.
  • the method comprises administering to a site of osteopenic or osteoporotic bone, or a site of low bone mass or density, an effective amount of a composition comprising at least one active agent which is capable of inducing growth of bone or increasing the formation of bone tissue or reducing bone loss at the site.
  • Bone mass is commonly designated “bone mineral content” or BMC and is measured in grams.
  • Bone density is commonly designated “bone mineral density” or BMD and is expressed as grams per unit area or grams per unit volume.
  • the mode of administration is by intraosseous injection.
  • the active agent is one or more proteins selected from the group of proteins known as the Transforming Growth Factors-Beta (TGF- ⁇ ) superfamily of proteins, preferably selected from the Bone Morphogenetic Proteins (BMPs), the Growth and Differentiation Factors (GDFs), as well as other proteins, as described more fully herein.
  • TGF- ⁇ Transforming Growth Factors-Beta
  • BMPs Bone Morphogenetic Proteins
  • GDFs Growth and Differentiation Factors
  • the methods and compositions of the present invention are advantageous in that they provide a localized treatment for osteoporosis or osteopenic bone, rather than systemic treatment.
  • the present invention is further advantageous in that it utilizes as active agents osteogenic proteins, which may be produced via recombinant DNA technology, and therefore are of potentially unlimited supply.
  • the methods and compositions of the present invention are further advantageous in that regeneration of the bone tissue increases the bone mass/density, increase the bone strength, and thereby reduce the severity of osteoporosis or incidence of osteoporotic lesions, ultimately lessening the incidence of bone fractures.
  • the active agents are administered locally through injection using a suitable buffer and/or carrier.
  • a suitable buffer comprises glycine, sucrose, and glutamic acid hydrochloride, at a pH of less than 6.0.
  • this formulation comprises about 2.5% glycine (g/100 ml (w/v)), about 0.5% sucrose (w/v), about 5 mM glutamic acid hydrochloride (about 0.1% w/v), and about 0.01 % (w/v) polysorbate 80, at a pH of about 4.5.
  • This buffer is referred to later in this application as "MFR 842.” Further buffers suitable for use in the present invention are described in United State Patent 5,385,887, the disclosure of which is hereby incorporated by reference.
  • Suitable carriers include collagen gels, hyaluronate, alginates and hyaluronic acids, injectable calcium phosphates, polyols, demineralized bone matrix and combinations of the above.
  • Other carriers which may be useful for the present invention include blood as well as clotting proteins, such as fibrin or thrombin, and oils.
  • the active agent further comprises, in addition to one or more proteins selected from the TGF- ⁇ superfamily of proteins, one or more auxiliary proteins, such as Hedgehog, Noggin, Chordin, Frazzled, Cerberus and
  • compositions of the present invention may be useful for injectable formulations of BMPs for uses such as injection into joints for treatment and repair of osseous defects, cartilage defects, inhibition of cartilage degradation and to promote cartilage repair.
  • the formulations may also be injected into tendons, ligaments and/or their attachment sites to bone.
  • injectable formulations of BMPs may also find application to other bone sites such as bone cysts, implants into bones, closed fractures and distraction osteogenesis.
  • the methods comprise applying to the osteoporotic or osteopenic site an amount of a composition comprising one or more purified osteogenic proteins which is effective to induce the formation and/or maintenance of bone.
  • the active agent is preferably selected from the family of proteins known as the transforming growth factors-beta (TGF- ⁇ ) superfamily of proteins, which includes the activins, inhibins and bone morphogenetic proteins (BMPs).
  • TGF- ⁇ transforming growth factors-beta
  • BMPs bone morphogenetic proteins
  • the active agent includes at least one protein selected from the subclass of proteins known generally as BMPs, which have been disclosed to have osteogenic activity, and other growth and differentiation type activities.
  • BMPs include BMP proteins BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7, disclosed for instance in United States Patents 5,108,922; 5,013,649; 5,116,738; 5,106,748; 5,187,076; and 5,141,905; BMP-
  • TGF- ⁇ proteins which may be useful as the active agent in the present invention include Vgr-2, Jones et al., Mol.
  • GDFs growth and differentiation factors
  • PCT applications WO94/15965; WO94/15949; WO95/01801; WO95/01802; WO94/21681 ; WO94/15966; WO95/10539; WO96/01845; WO96/02559 and others.
  • Also useful in the present invention may be
  • BIP disclosed in WO94/01557; HP00269, disclosed in JP Publication number: 7-250688; and MP52, disclosed in PCT application WO93/16099.
  • BMPs which are presently preferred for use in the present invention include BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP- 10, BMP-12 and BMP- 13.
  • the active agent is most preferably BMP-2, the sequence of which is disclosed in United States Patent 5,013,649, the disclosure of which is hereby incorporated by reference.
  • Other BMPs and TGF- ⁇ proteins known in the art can also be used.
  • the active agent may be recombinantly produced, or purified from a protein composition.
  • the active agent if a TGF- ⁇ such as a BMP, or other dimeric protein, may be homodimeric, or may be heterodimeric with other BMPs (e.g., a heterodimer composed of one monomer each of BMP-2 and BMP-6) or with other members of the TGF- ⁇ superfamily, such as activins, inhibins and TGF- ⁇ 1 (e.g., a heterodimer composed of one monomer each of a BMP and a related member of the TGF- ⁇ superfamily). Examples of such heterodimeric proteins are described for example in
  • the active agent may further comprise additional agents such as the Hedgehog, Frazzled, Chordin, Noggin, Cerberus and Follistatin proteins. These families of proteins are generally described in Sasai et al., Cell, 79:779-790 (1994) (Chordin);
  • the amount of active agent useful herein is that amount effective to stimulate increased osteogenic activity of present or infiltrating progenitor or other cells, and will depend upon the size and nature of the defect being treated, as well as the carrier being employed.
  • the amount of protein to be delivered is in a range of from about 0.1 to about 100 mg; preferably about 1 to about 100 mg; most preferably about 10 to about 80 mg.
  • CARRIER Materials which may be useful as the carrier in practicing the present invention include pharmaceutically acceptable materials having viscosity and polarity such that, when added to the bone morphogenetic protein, form a composition that possesses appropriate handling characteristics for injectable application to the site of osteoporotic or osteopenic bone. Adding the carrier to the bone morphogenetic protein allows the protein to remain in the diseased or lesioned site for a time sufficient to allow the protein to increase the otherwise natural rate of regenerative osteogenic activity of the infiltrating mammalian progenitor or other cells, and to form a space in which new tissue can grow and allow for ingrowth of cells.
  • the carrier may also allow the bone morphogenetic protein to be released from the disease or lesion site over a time interval appropriate for optimally increasing the rate of regenerative osteogenic activity of the progenitor cells.
  • the carrier may also supply a framework on which to induce new formation in severely osteoporotic bone.
  • the most preferred family of carriers comprises collagenous materials. These are preferably in a form suitable for injection, such as a gel. Such gels may be cross- linked or non-cross-linked. Other forms of collagen, such as dispersions or fibrillar collagen, may also be useful in the methods of the present invention.
  • Another preferred family of carriers is cellulosic materials such as alkylcellulose, including hydroxyalkylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being the cationic salts of carboxymethylcellulose (CMC).
  • CMC carboxymethylcellulose
  • the carrier be in the form of a hydrated cellulosic viscous gel. Viscosity may be increased through mechanical means, such as high agitation for a suitable period of time, followed by autoclaving, or chemically.
  • the active agent and cellulosic carrier is preferably in a solution of suitable buffer.
  • One preferred buffer solution is a composition comprising, in addition to the active agent, about 1.0 to about 10.0%
  • (w/v) glycine about 0.1 to about 5.0% (w/v) of a sugar, preferably sucrose, about 1 to about 20 mM glutamic acid hydrochloride, and optionally about 0.01 to about 0.1% of a non-ionic surfactant, such as polysorbate 80.
  • Preferred solutions are from about 1 % to about 20% w/v cellulosic carrier/buffer. If desired, a salt may be added.
  • a preferred viscous gel carrier is described in Example 2 below.
  • the amount of osteogenic protein useful with viscous gel carrier is generally in a range of from about 0.1 to about 100 mg, preferably about 1 to about 100 mg; most preferably about 10 to about 80 mg per cubic centimeter of implant material required.
  • Resorbable hydroxyapatites as well as minerals, ceramics and phosphates.
  • Resorbable hydroxyapatites can be formulated at various porosities with varying resorption rates; their handling characteristics vary from hard implantable types, to gel-like consistency, to those that are injectable but harden at body temperature.
  • Suitable hydroxyapatite and ceramic carriers are described, for example in WO96/36562; and United States Patents 5,543,019; 5,306,305; 5,258,044; 5,496,399;
  • injectable polymers which may be viscous and which may optionally include a sequestering agent as well.
  • Suitable polymers and sequestering agents include those described in United States Patent 5,171,579, the entire disclosure of which is incorporated herein by reference.
  • Other polymers include the pluronics, such as Poloxamer 407 gel.
  • Pluronics are a class of water soluble ABA type block surfactant copolymers which exhibit the unique property of reverse thermal gelation. They are liquid (and hence syringeable) at 4°C and gel at body temperature.
  • Poloxamer 407 MW 12,500, is excreted unchanged in the urine after systemic absorption and has supposedly been shown to be non-toxic in animals.
  • Polylactides and/or polyethylene glycols including poly(lactide)/poly(ethylene glycol) gels.
  • Polylactides may be dissolved in polyethylene glycols, such as low molecular weight (2000) PLA dissolved in PEG to produce a syringeable solution that precipitates PLA upon injection into an aqueous environment, resulting in a relatively firm gel.
  • the literature cites conjugates, such as Poly(lactic acid)-poly(ethylene glycol) conjugates, as appropriate carriers for BMPs (Miyamoto et al., Clin. Orthop. Rel. Res.
  • fibrin-based polymers in liquid or gel form.
  • materials useful as sequestering agents are hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly( vinyl alcohol), and cellulosic materials, such as hydroxycelluloses.
  • One such preferred agent is carboxymethylcellulose.
  • the solid material may be combined with a viscous liquid carrier for ease and uniformity of administration.
  • the carrier may optionally be combined with a diluent, such as aqueous glycerol, preferably the carrier diluent would be present in concentrations of about 10 to about 80% (v/v).
  • a diluent such as aqueous glycerol
  • the carrier diluent would be present in concentrations of about 10 to about 80% (v/v).
  • the above materials may be combined in particular embodiments of the present invention.
  • polymers such as porous particulate polymers, may be dissolved or suspended in cellulosic or gel carriers to increase viscosity.
  • the active agents are administered locally through injection using only a suitable buffer as carrier.
  • a suitable buffer comprises glycine, sucrose, and glutamic acid hydrochloride, at a pH of less than 6.0.
  • Preferred compositions of buffer solutions comprise about 1.0 to about 10.0% (w/v) glycine, about 0.1 to about 5.0% (w/v) of a sugar, preferably sucrose, about 1 to about 20 mM glutamine, glutamic acid, or glutamic acid hydrochloride, and optionally about 0.01 to about 0.1 % of a non-ionic surfactant, such as polysorbate 80.
  • this formulation comprises about 2.5% glycine (g/100 ml (w/v)), about 0.5% sucrose (w/v), about 5 mM glutamic acid hydrochloride (about 0.1% w/v), and about 0.01% (w/v) polysorbate 80, at a pH of about 4.5.
  • This buffer has been described as MFR 842.
  • buffers suitable for use in the present invention are described in United State Patent 5,385,887, the disclosure of which is hereby incorporated by reference.
  • Preferred solutions may also include combinations of buffer and other carrier, such as a combination of buffer and cellulosic carrier. Preferred ranges for this combination are from about 1% to about 20% w/v cellulosic carrier/buffer. If desired, a salt may be added.
  • the injectable compositions of the present invention may be administered in any clinically acceptable manner of injection.
  • a number of commercially available syringes may be suitable for use in the present invention, and for administration of the compositions of the present invention.
  • suitable syringes are available the Calasept R syringe [JS Dental Manufacturing, Ridgefield CT] comprises sterile calcium hydroxide paste in isotonic saline solution, in a non-aspirating or modified aspirating cartridge syringe; Henke-Ject Aspirating Syringe and Hypo Brand Dental Syringes/Needles [Smith & Nephew MPL, Franklin Park, LL]; intraosseous needles from MPL, Inc., Chicago LL; and Luer-Lok R Syringes [Becton Dickinson, Franklin Lakes, NJ], may all be appropriate syringes for use in the present invention.
  • bone morphogenetic proteins are used as an osteoinductive agent in the process known as distraction osteogensis.
  • This process is an alternative to segmental bone regeneration in response to implanted osteoinductive agents.
  • the osteoinductive agent and carrier are placed in the defect created between the parent bone ends.
  • the osteoinductive agent has to have sufficient residence time in the defect to stimulate differentiation of sufficient numbers of bone forming cells to support new bone formation.
  • the carrier also has to have sufficient residence time to serve as a scaffold for bone forming cells to attach (osteoconduction).
  • the carrier also has to have sufficient porosity to allow cells and blood vessels to penetrate into the defect for bone formation to occur.
  • the process of distraction osteogenesis creates a regenerate construct between the distracted parent bone ends that is highly vascular and contains a large population of mesenchymal stem cells destined to become bone forming cells.
  • the regenerate construct represents a much more ideal environment for cell differentiation growth factors such rhBMP-2 to stimulate rapid bone induction relative to induction of bone within a segmental defect.
  • the process of distraction osteogenesis begins with an initial latency period allowing a fibrous connection to form between the bone ends to be distracted.
  • the bone ends are slowly distracted at a controlled rate of up to 1 mm per day in human clinical cases.
  • a prolonged consolidation period is required to allow the regenerate to form bone. This prolonged consolidation period which can be on the order 4 to 6 months is associated with considerable morbidity.
  • a frequent complication is the occurrence of pin track infections resulting from the extended length of time the external fixator used to generate the distraction must remain in place.
  • the regenerate does not form properly and a delayed union or non-union occurs.
  • the regenerate contains a responsive cell population and is already highly vascularized following the initial distraction phase, the use of bone morphogenetic proteins may rapidly accelerate the rate of bone formation during the normally prolonged consolidation phase of distraction osteogenesis. Acceleration of the distraction phase is limited by stretching of the soft tissues associated with bone.
  • the cells created using distraction osteogenesis may also be harvested in order to provide a source of cells which are primed for osteogenesis. These cells can be cultured to prepare immortalized cell lines. If desired, these cells can also be immunotolerized using agents such as CTLA4 receptors [U.S. Patent 5,434,131] or CTLA4 ligands or B7 monoclonal antibodies [WO 96/40915]. Methods and materials for such immunotolerization are disclosed in the above references, and include co- transfection or treatment with these factors. The disclosure of these references is hereby incorporated herein by reference.
  • the oophorectomized rat is a well-established model of osteoporosis and its use is recommended by the FDA as one of the animal models to be employed in demonstrating efficacy of potential therapeutic agents for osteoporosis.
  • Preclinical studies testing the efficacy of rhBMP-2 in the oophorectomized rat model of osteoporosis demonstrated that 100 Mg rhBMP-2 in MFR 842 buffer, injected into the intramedullary space of the tibial shaft, was associated with extensive bone formation. Further evaluation with this model is conducted at lower doses.
  • rat tibiae are injected with 0, 10, or 50 Mg of rhBMP-2 in 20 ML MFR 842 buffer.
  • Controls include sham ovariectomized animals [surgery performed, but ovaries are not removed], buffer injections and sham surgeries.
  • the femora are harvested and groups analyzed by DEXA, biomechanics, and histornorphometry.
  • Intraosseous administration of injectable rhBMP-2 is accomplished in the non-fractured (contralateral) femur using an operating room, biplanar fluoroscopy, and patient positioning on a fracture table. Each patient undergoes the necessary surgical treatment of the fractured femur. At the completion of surgical procedure, but before termination of the anesthesia, the lower extremities are repositioned on the fracture table to gain access to the uninjured contralateral hip. Under sterile conditions and biplanar image intensifier visualization, the designated dose of rhBMP-
  • Example 2 is delivered by percutaneous, intraosseous route into the proximal femur.
  • Follow-up evaluations include radiographic assessment, clinical evaluation of infection and fracture, and DEXA evidence of bone formation.
  • Example 6 Rabbit Ulnar Osteotomy and Fracture Models. In the osteotomy model, the ulna is simply exposed, the periosteum is stripped, and a 2 to 5 mm osteotomy created using an oscillating saw. The incision is then closed, and the appendage bandaged to provide additional stability. Bilateral surgeries may be used in order to compare active agent against untreated or control substances.
  • the rabbit ulnar fracture model is similar to the rat femoral fracture model.
  • the rabbit ulnar fracture model relies on a weight-driven blunt instrument to create the fracture essentially using incident three-point bending.
  • the fracture is created by fully extending and clamping the forelimb to an aluminum rod containing two vertical bars.
  • a 23G needle is placed in between the radius and ulna to serve as a guide pin.
  • the blunt guillotine is then positioned, and a 850 gm weight raised to 45 cm and allowed to fall to create the fracture.
  • Poly(lactide)/poly(ethylene glycol) gels Low molecular weight (2000) PLA dissolved in PEG produces a syringeable solution that precipitates PLA upon injection into an aqueous environment, resulting in a relatively firm gel. Two different percentages were tested. 4. Poly(lactic acid)-poly(ethylene glycol) conjugates. Each material was implanted with 0, 10, and 80 ⁇ g rhBMP-2. Lyophilized rhBMP-2 was mixed with the gels using a mortar and pestle. The buffer, Pluronic gels, and PEG/PLA gels were first injected into blood clots. The PLA-PEG conjugates were implanted directly into the subcutaneous space. Six implants (three animals) were used per group. In addition, the intramuscular injection technique was investigated using the PLA/PEG gel and one Pluronic gel (both at the high dose only).
  • Bone score is a semi-quantitative measurement of the area of bone present in representative histological sections; the score ranges from 0 for no bone present, to 5 when the entire section consists of bone.
  • the Pluronics produced relatively little bone at the lower dose of rhBMP-2, and induced none when placed intramuscularly. Presumably the material does not have a long enough residence time, or does not sequester rhBMP-2 sufficiently. In addition, a significant inflammatory response was noted.
  • the PLA/PEG gels produced reasonable quantities of bone, with some residual matrix observed (presumably the precipitated PLA) along with a foreign body giant cell response.
  • the PLA-PEG conjugates produced well-defined ossicles of bone with bone marrow. Of the gels tested, this material performed best. Based on the samples tested, the intramuscular implantation appeared to be a more rigorous test of materials. In this experiment, rhBMP-2 in buffer simply injected into blood clot performed the best overall; presumably the rhBMP-2 is able to rapidly distribute and bind to the blood clot.
  • Various collagen materials tested include 2% LLS dispersion, 2% HeliteneTM dispersion, 2% Helistat® dispersion, the Zimmer collagen gel, and another collagen gel (6.5%) from Matrix Pharmaceuticals. All have been placed at 0, 20, and 80 ⁇ g rhBMP-2 and analyzed histologically.
  • BMP-2 may accelerate the consolidation (bone formation or mineralization) phase in a rabbit model of limb lengthening. Osteotomies are created in rabbit tibia.
  • the tibia are then be distracted 2 cm over a period of approximately ten days. Following the distraction phase, rhBMP-2 is administered. Two modes of application are tested. One set of animals has rhBMP-2/ACS (1.5 mg/mL; 0.075 mg/tibia) surgically placed within the regenerate. The second group of animals has rhBMP-2/MFR842 buffer (0.75 mg/mL; 0.075 mg/tibia) percutaneously injected into three sites within the regenerate. A third group of control animals has surgical intervention similar to the rhBMP-2/ACS-treated animals, with placement of ACS/buffer within the regenerate. Additional sets of animals have distraction performed, with no surgical intervention. Groups of animals are sacrificed at 5, 14 and 24 days. Radiographs are taken following the distraction phase and at sacrifice and are used to evaluate new bone formation in response to treatment and control.
  • Bone density within the defect is determined with Dual Energy X-Ray Absorptiometry and Peripheral Quantitative Computed Tomography (pQCT).
  • pQCT Peripheral Quantitative Computed Tomography
  • the three dimensional distribution of bone within the defect is evaluated with pQCT. Histological evaluation of non-decalcified specimens is used to quantify histomorphometric parameters. Results to date indicate a visually detectable acceleration of bone induction in rhBMP-2/ ACS treated animals compared to untreated surgical controls at 5 days and 14 days based on radiographic evaluation.
  • the DXA and pQCT images confirm these findings.
  • the pQCT images indicate greater three-dimensional distribution of bone within the regenerate and evidence of early stages of corticalization in the rhBMP-2/ACS treated animals at 14 days.
  • rhBMP-2/ ACS treatment effect of significant acceleration of the consolidation phase of distraction osteogenesis. Formation of an intact cortex is the primary indicator for removal of the external fixator and associated return to unprotected full weight bearing.
  • the rhBMP-2/MFR842 injection buffer treatment is the preferred route of administration having more wide spread application in primary distraction osteogenesis.

Abstract

L'invention concerne des procédés et des compositions destinés au traitement d'anomalies et de maladies entraînant une ostéoporose ou des affections ostéopéniques. Les procédés comprennent l'application sur le site d'affections ostéoporotiques ou ostéopéniques d'une composition renfermant un agent actif appartenant de préférence à la superfamille de protéines TGF-β. Les avantages que présente cette invention sont notamment de réduire la gravité et/ou la fréquence de fractures des os, ou d'éviter que celles-ci ne se produisent. Les procédés de l'invention présentent également l'avantage d'une administration locale plutôt que systémique.
PCT/US1998/001143 1997-01-21 1998-01-21 Formulations injectables destinees au traitement d'os osteoporotiques WO1998031788A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62458/98A AU6245898A (en) 1997-01-21 1998-01-21 Injectable formulations for treatment of osteoporotic bone

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3586597P 1997-01-21 1997-01-21
US60/035,865 1997-01-21
US908598A 1998-01-20 1998-01-20
US09/009,085 1998-01-20

Publications (1)

Publication Number Publication Date
WO1998031788A1 true WO1998031788A1 (fr) 1998-07-23

Family

ID=26679027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/001143 WO1998031788A1 (fr) 1997-01-21 1998-01-21 Formulations injectables destinees au traitement d'os osteoporotiques

Country Status (2)

Country Link
AU (1) AU6245898A (fr)
WO (1) WO1998031788A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020021A1 (fr) * 1998-10-06 2000-04-13 Stryker Corporation Reparation du larynx, de la trachee et d'autres tissus fibrocartilagineux
WO2000044413A1 (fr) * 1999-02-01 2000-08-03 Genetics Institute, Inc. Procedes et compositions permettant la cicatrisation et la reparation du cartilage articulaire
WO2002085422A1 (fr) 2001-04-25 2002-10-31 Eidgenössische Technische Hochschule Zürich Matrices pour l'administration de medicaments destinees a ameliorer la cicatrisation
AU771382B2 (en) * 1999-02-01 2004-03-18 Genetics Institute, Llc Methods and compositions for healing and repair of articular cartilage
US6958149B2 (en) 1998-10-06 2005-10-25 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
EP1649865A1 (fr) * 1998-10-06 2006-04-26 Stryker Corporation Utilisation de protéines ostéogènes pour la fabrication d'une composition pharmaceutique pour le treaitement de défauts dans le cartilage non-articulaire
CN100435859C (zh) * 1999-02-01 2008-11-26 遗传研究所公司 用于关节软骨愈合和修复的骨软骨移植物的制备方法和组合物
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US7622139B2 (en) 2001-06-08 2009-11-24 Wyeth Calcium phosphate delivery vehicles for osteoinductive proteins
AU2004272072B2 (en) * 2003-09-12 2010-07-08 Etex Corporation Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
US8226942B2 (en) 2007-12-28 2012-07-24 Kuros Biosurgery Ag PDGF fusion proteins incorporated into fibrin foams

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166058A (en) * 1986-07-01 1992-11-24 Genetics Institute, Inc. DNA sequences encoding the osteoinductive proteins
WO1993000050A1 (fr) * 1991-06-21 1993-01-07 Genetics Institute, Inc. Compositions pharmaceutiques de proteines osteogeniques
US5453419A (en) * 1989-09-06 1995-09-26 Chichibu Cement Co., Ltd. Xenopus laevis bone morphogenetic proteins and use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166058A (en) * 1986-07-01 1992-11-24 Genetics Institute, Inc. DNA sequences encoding the osteoinductive proteins
US5453419A (en) * 1989-09-06 1995-09-26 Chichibu Cement Co., Ltd. Xenopus laevis bone morphogenetic proteins and use thereof
WO1993000050A1 (fr) * 1991-06-21 1993-01-07 Genetics Institute, Inc. Compositions pharmaceutiques de proteines osteogeniques
US5597897A (en) * 1991-06-21 1997-01-28 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
REDDI ET AL.: "Osteoporosis (chapter 9, p. 281-287)", 1996, ACADEMIC, SAN DIEGO, CALIF., XP002065501 *
TAGAKI ET AL.: "The role of bone marrow in bone morphogenetic protein-induced repair of femoral massive diaphyseal defects", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, vol. 171, 1982, pages 224 - 231, XP002065500 *
WANG: "Bone morphogenetic proteins (BMPS): Therapeutic potential in healing bony defects", TRENDS IN BIOTECHNOLOGY, vol. 11, no. 9, 1993, pages 379 - 383, XP002065499 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803369B2 (en) 1998-10-06 2010-09-28 Stryker Corporation Devices and method for repair of larynx, trachea, and other fibrocartilaginous tissues
US8673853B2 (en) 1998-10-06 2014-03-18 Stryker Corporation Method and device for repairing the larynx, trachea and other fibrocartilaginous tissues
US8354375B2 (en) 1998-10-06 2013-01-15 Stryker Corporation Repair of ligament using osteogenic proteins
EP2374870A3 (fr) * 1998-10-06 2012-03-14 Stryker Corporation Utilisation de op-1 pour la préparation d'une composition pharmaceutique destinée à préparer la réparation de défauts du cartilage non-articulaire d'un mammifère
USRE42954E1 (en) 1998-10-06 2011-11-22 Stryker Corporation Method for repairing a defect in an intervertebral disc
WO2000020021A1 (fr) * 1998-10-06 2000-04-13 Stryker Corporation Reparation du larynx, de la trachee et d'autres tissus fibrocartilagineux
US6958149B2 (en) 1998-10-06 2005-10-25 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
EP1649865A1 (fr) * 1998-10-06 2006-04-26 Stryker Corporation Utilisation de protéines ostéogènes pour la fabrication d'une composition pharmaceutique pour le treaitement de défauts dans le cartilage non-articulaire
US7842669B2 (en) 1999-02-01 2010-11-30 Genetics Institute, Llc Methods and compositions for healing and repair of articular cartilage
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
WO2000044413A1 (fr) * 1999-02-01 2000-08-03 Genetics Institute, Inc. Procedes et compositions permettant la cicatrisation et la reparation du cartilage articulaire
EP2174674A1 (fr) * 1999-02-01 2010-04-14 Genetics Institute, LLC Procédés et compositions permettant la cicatrisation et la réparation du cartilage articulaire
US7749964B2 (en) 1999-02-01 2010-07-06 Wyeth Llc Methods and compositions for healing and repair of articular cartilage
AU771382B2 (en) * 1999-02-01 2004-03-18 Genetics Institute, Llc Methods and compositions for healing and repair of articular cartilage
CN100435859C (zh) * 1999-02-01 2008-11-26 遗传研究所公司 用于关节软骨愈合和修复的骨软骨移植物的制备方法和组合物
EP1400252A1 (fr) * 1999-02-01 2004-03-24 Genetics Institute, LLC Procédés et compositions permettant la cicatrisation et la réparation du cartilage articulaire
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US8309518B2 (en) 2001-04-25 2012-11-13 Eidgenossische Technische Hochschule Zurich Drug delivery matrices to enhance wound healing
WO2002085422A1 (fr) 2001-04-25 2002-10-31 Eidgenössische Technische Hochschule Zürich Matrices pour l'administration de medicaments destinees a ameliorer la cicatrisation
US8003133B2 (en) 2001-06-08 2011-08-23 Wyeth Llc Calcium phosphate delivery vehicles for osteoinductive proteins
US7622139B2 (en) 2001-06-08 2009-11-24 Wyeth Calcium phosphate delivery vehicles for osteoinductive proteins
AU2004272072B2 (en) * 2003-09-12 2010-07-08 Etex Corporation Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
US8226942B2 (en) 2007-12-28 2012-07-24 Kuros Biosurgery Ag PDGF fusion proteins incorporated into fibrin foams

Also Published As

Publication number Publication date
AU6245898A (en) 1998-08-07

Similar Documents

Publication Publication Date Title
Seeherman et al. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate model
Den Boer et al. Effect of recombinant human osteogenic protein-1 on the healing of a freshly closed diaphyseal fracture
JP3191937B2 (ja) 骨誘導医薬製剤
US7875590B2 (en) Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
Bouxsein et al. Recombinant human bone morphogenetic protein-2 accelerates healing in a rabbit ulnar osteotomy model
AU669133B2 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
KIRKER‐HEAD Recombinant bone morphogenetic proteins: novel substances for enhancing bone healing
EP1220693B1 (fr) Formulations destinees a l'administration de proteines osteogeniques
US20110117018A1 (en) Compositions and methods for treating bone
EP3697459B1 (fr) Substitut de greffe osseuse autologue
Miyazaki et al. A porcine collagen-derived matrix as a carrier for recombinant human bone morphogenetic protein-2 enhances spinal fusion in rats
Kuroiwa et al. Escherichia coli-derived BMP-2-absorbed β-TCP granules induce bone regeneration in rabbit critical-sized femoral segmental defects
WO1998031788A1 (fr) Formulations injectables destinees au traitement d'os osteoporotiques
Huang et al. Effect of ErhBMP-2-loaded β-tricalcium phosphate on ulna defects in the osteoporosis rabbit model
Ren et al. Effects of rhBMP-2/7 heterodimer and RADA16 hydrogel scaffold on bone formation during rabbit mandibular distraction
US11596712B2 (en) Autologous bone graft substitute composition
RU2727241C2 (ru) Образование кости
Love et al. Mesenchymal stem cells enhance targeted bone growth from injectable hydrogels with BMP‐2 peptides
Ripamonti et al. Local delivery of bone morphogenetic proteins in primates using a reconstituted basement membrane gel: tissue engineering with Matrigel: research in action
Munns et al. Role of osteogenic protein-1/bone morphogenetic protein-7 in spinal fusion
Kacena et al. Novel therapy for bone regeneration in large segmental defects
EP1475109A1 (fr) Formulations destinées a l'administration de protéines osteogéniques
Chu et al. Novel Therapy for Bone Regeneration in Large Segmental Defects
KR20050019075A (ko) 골형성 단백질의 전달을 위한 주사가능한 고체 히알루론산담체

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998534670

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase